The collective findings not only establish an empirical foundation for using honokiol in the clinical management of depression but also propose the possibility of the HIF-1α-VEGF pathway as a viable therapeutic target for depression treatment [75]. This evidence concerns the gene HIF1A and depressive symptom measurement.